Novel quinoline derivatives were initially identified as candidate Tau PET tracers by the screening of over 2000 small molecules [87], with the initial selection of the [18F]THK523 agent, which failed to visualize the Tau deposits clearly in patients with AD [74]. Here, MAPT is linked to Alzheimer disease.